Editas Medicine Stock Analysis

Editas Stock Analysis Notes

About 54.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 2.35. Editas Medicine had not issued any dividends in recent years. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Editas Medicine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 264 people. To learn more about Editas Medicine call Gilmore MD at 617 401 9000 or check out https://www.editasmedicine.com.

Editas Medicine Investment Alerts

Editas Largest EPS Surprises

View All Earnings Estimates

Editas Stock Institutional Investors

Note, although Editas Medicine's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Editas Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 164 M.

Editas Profitablity

Management Efficiency

Editas Medicine has return on total asset (ROA) of (0.2826) % which means that it has lost $0.2826 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1137) %, meaning that it created substantial loss on money invested by shareholders. Editas Medicine's management efficiency ratios could be used to measure how well Editas Medicine manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.66 in 2026. Return On Capital Employed is likely to drop to -0.9 in 2026. Liabilities And Stockholders Equity is likely to gain to about 394.2 M in 2026, whereas Total Current Liabilities is likely to drop slightly above 44.6 M in 2026.

Technical Drivers

As of the 13th of February 2026, Editas Medicine shows the Variance of 21.27, standard deviation of 4.61, and Mean Deviation of 3.3. Editas Medicine technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.

Editas Medicine Price Movement Analysis

Editas Medicine Insider Trading Activities

Editas Medicine Outstanding Bonds

Editas Medicine Predictive Daily Indicators

Editas Medicine Forecast Models

Editas Medicine's time-series forecasting models are one of many Editas Medicine's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Editas Medicine's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Editas Medicine Bond Ratings

Editas Medicine financial ratings play a critical role in determining how much Editas Medicine have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Editas Medicine's borrowing costs.

Editas Medicine Debt to Cash Allocation

Editas Medicine currently holds 35.03 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Editas Medicine has a current ratio of 12.42, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Editas Medicine's use of debt, we should always consider it together with its cash and equity.

Editas Medicine Total Assets Over Time

Editas Medicine Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Editas Medicine uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Editas Medicine Debt Ratio

11.0

It appears most of the Editas Medicine's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Editas Medicine's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Editas Medicine, which in turn will lower the firm's financial flexibility.

Editas Medicine Corporate Bonds Issued

Editas Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Editas Medicine prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Editas shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Editas Medicine. By using and applying Editas Stock analysis, traders can create a robust methodology for identifying Editas entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Editas analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Editas analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Editas Medicine stock analysis indicators help investors evaluate how Editas Medicine stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Editas Medicine shares will generate the highest return on investment. By understating and applying Editas Medicine stock analysis, traders can identify Editas Medicine position entry and exit signals to maximize returns.

When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.